How to treat lupus nephritis

"The treatment of lupus nephritis" and other issues of concern are the majority of patients, Shijiazhuang kidney hospital for brief treatment of lupus nephritis
Lupus nephritis (LN) is the most common secondary glomerulonephritis, the clinical diagnosis and treatment is very complex. Recently held the first Chinese renal physician at the annual meeting, Ruijin Hospital of Shanghai Second Medical University, Professor Chen Nan said: "master of lupus nephritis, essentially mastered a nephrology." She pointed out, the disease to be considered pathological type, attention to individualized treatment; biological immunosuppressive agents to treat the disease has broad application prospects. Individualized drug therapy according to statistics, about 3% to 9% of systemic lupus erythematosus (SLE) patients with renal involvement, only the first manifestation of the pathological type. The clinical manifestations of kidney damage accounted for 35% to 90% of patients with SLE; if the combination of immune pathology, almost all SLE patients have varying degrees of renal involvement. Accordance with the pathological type, LN can be divided into six categories. Professor Chen Nan, should be based on clinical manifestations, renal pathological type of development of different treatment programs. The renal pathological types can help determine prognosis and treatment plan, a reasonable choice of immunosuppressive agents. Significant renal involvement performance, renal tissue disease was type I (minimal change) are the only immune serum examination exception, generally do not need a powerful hormone and immunosuppressive therapy, we recommend close follow-up condition changes. Skin or joint disease may be given hydroxychloroquine; was light with mild systemic manifestations of clinical pathology was type II (mesangial proliferative) were given to small and medium-dose hormone; type III (focal) in active lesions more limited cases using medium-dose hormone therapy is better, more serious type III cases, using the same method and type IV; type III and type IV (diffuse), high activity index should be phased (induction phase and maintenance phase) treatment for diffuse proliferative damage and acute renal failure, induction of high dose glucocorticoids and immunosuppressive therapy; large doses of hormones are generally not in favor of the simple V-shaped (membrane) treatment and adjustment of hormone dose is more according to the extra-renal manifestations; can type VI (advanced sclerosing) Pathological hardening of the main activity indicators are not significant, small doses of hormones to maintain.